AI-generated from publicly available materials.DeepIntent has unveiled Cora, an innovative AI-driven marketing platform designed to streamline healthcare advertising as the complexity of pharma marketing increases.
Following a significant investment from Vitruvian Partners, DeepIntent has launched Cora, a platform equipped with multiple AI agents that facilitate healthcare marketers in executing tasks through conversational interfaces. This platform aims to optimize various stages of campaign planning, including data analysis and audience strategy development, and integrates with VideoAmp to extend its capabilities to linear TV advertising.
In initial testing, Cora has demonstrated a remarkable ability to reduce marketing planning cycles by 50%, with a majority of users reporting enhanced workflow efficiency. DeepIntent's CEO, Chris Paquette, emphasizes that as pharmaceutical companies develop more specialized medications for limited patient populations, the need for precise ad targeting will become increasingly critical. This trend is underscored by the fact that over 100 AI-developed drugs are currently undergoing early-stage FDA trials, many aimed at rare conditions affecting small patient groups.
Furthermore, DeepIntent plans to enhance Cora by integrating additional data sources related to payers and drug coverage, utilizing the Helix application to ensure patient privacy is maintained. As Paquette notes, the development of a robust data-driven advertising system has resulted in one of the most comprehensive healthcare market datasets available, positioning DeepIntent as a key player in the evolving landscape of pharma marketing.